This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRadimed (IRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
IRADIMED (IRMD) reports growth across all operating segments and geographies
IRadimed (IRMD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 23.08% and 1.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Buy Stocks for December 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
New Strong Buy Stocks for December 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 40.00% and 2.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
iRadimed Corporation (IRMD) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
iRadimed Corporation (IRMD) Sees Hammer Chart Pattern: Time to Buy?
Top Ranked Momentum Stocks to Buy for May 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 29th:
Zacks.com featured highlights include: Lindblad, Cleveland-Cliffs, Marine Products, IRadimed and ChannelAdvisor
by Zacks Equity Research
Zacks.com featured highlights include: Lindblad, Cleveland-Cliffs, Marine Products, IRadimed and ChannelAdvisor
5 Breakout Stocks Offering Extraordinary Returns
by Swarup Gupta
This technique seeks to identify those stocks whose prices are varying within a specific band.
IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
IDEXX Laboratories, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for IDXX for clues.
IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Positive tidings on the regulatory front drive IRadimed's (IRMD) growth. The company's solid guidance is also encouraging.
Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT
by Zacks Equity Research
Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT
5 Cheap Breakout Stocks Offering Strong Returns
by Swarup Gupta
This technique seeks to identify those stocks whose prices are varying within a specific band.
IRADIMED (IRMD) MRidium Magnetic MRI Gets FDA Approval
by Zacks Equity Research
IRADIMED CORPORATION (IRMD) recently announced the receipt of 510(k) clearance for its MRidium 3860+ magnetic MRI compatible IV infusion pump system, which features the Dose Error Reduction System software (DERS).
4 Medical Instrument Makers to Save Your Portfolio
by Jeremy Mullin
Technology in the medical world is leading these companies to breakthrough devices, which save and extend lives.